Premedium Pharmaceuticals Private Limited, a active private limited company, was established on 09 October 2018 in Delhi, Delhi, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24200DL2018PTC340319. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹22.00 Cr and a paid-up capital of ₹21.79 Cr.
It upholds a compliant status. Employing 12 professional, Its leadership includes Sanjiv Kumar Kothari (Director), Saras Malik (Director), Dilip Birdi (Whole-Time Director). Past directors included Rakesh Haldia, Ritesh Kumar, Saras Malik. It holds no open charges and ₹1.00 Cr settled loans. Its latest AGM occurred on 27 June 2025, with the balance sheet filed on 31 March 2025. It is based at Plot No. 14, Sector - 20, Dwarka, Delhi, Delhi, 110075.
U24200DL2018PTC340319
340319
09 October 2018
₹22.00 Cr
₹21.79 Cr
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Premedium Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sanjiv Kumar Kothari | Director | 09 Oct 2018 | Current |
| Saras Malik | Director | 14 Aug 2019 | Current |
| Dilip Birdi | Whole-Time Director | 30 Dec 2019 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Cfo(Kmp) | - | Past |
| Pramod Abcsdd | Company Secretary | - | Past |
| Pramod Abcsdd | Additional Director | 30 Dec 2019 | Past |
| Pramod Abcsdd | Company Secretary | - | Past |
| Pramod Abcsdd | Additional Director | 02 Aug 2019 | Past |
| Pramod Abcsdd | Cfo(Kmp) | 30 Jun 2022 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Premedium Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 23.7% decrease. The company also saw a substantial improvement in profitability, with a 30.76% increase in profit. The company's net worth observed a substantial decline by a decrease of 136.47%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2021, Premedium Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹10,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Aug 2019 | Others | ₹1.00 Cr | Satisfied |
Explore comprehensive loan charge details -
Premedium Pharmaceuticals has a workforce of 12 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Premedium Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Premedium Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Premedium Pharmaceuticals Private Limited last Annual general meeting of members was held on 27 Jun 2025 as per latest MCA records. was documented.
Premedium Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi. was recorded as a recent event.
The activity Amit Kumar was appointed as a Company Secretary was appointed as a Company Secretary on 20 Mar 2023 & has been associated with this company since 2 years 8 months . was completed.
The activity A charge registered on 13 Aug 2019 via Charge ID 100286768 with Others was fully satisfied on 13 Feb 2023. was completed.
A charge with Others of Rs. 1.00 Cr registered on 13 Aug 2019 with Charge ID 100286768 was modified on 15 Oct 2022. was recorded as a recent event.
The activity Vivek Anand was appointed as a CFO was appointed as a CFO on 15 Sep 2022 & has been associated with this company since 3 years 2 months . was completed.
The CIN of Premedium Pharmaceuticals Private Limited is U24200DL2018PTC340319.
Premedium Pharmaceuticals Private Limited is headquartered at Plot No. 14, Sector - 20, Dwarka, Delhi, Delhi, 110075.
Premedium Pharmaceuticals Private Limited was incorporated on 09 October 2018.
The current directors of Premedium Pharmaceuticals Private Limited are
The primary industry of Premedium Pharmaceuticals Private Limited is Manufacturing.
Premedium Pharmaceuticals Private Limited is unlisted.
The authorized capital of Premedium Pharmaceuticals Private Limited is ₹22.00 Cr, and the paid-up capital is ₹21.79 Cr.
The compliance status of Premedium Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX